Advertisement
U.S. markets open in 3 hours 3 minutes

Delcath Systems, Inc. (DCTH)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
5.09+0.48 (+10.41%)
At close: 04:00PM EDT
5.10 +0.01 (+0.20%)
After hours: 07:52PM EDT

Delcath Systems, Inc.

1633 Broadway
22nd Floor Suite C
New York, NY 10019
United States
212 489 2100
https://www.delcath.com

Sector(s)Healthcare
IndustryMedical Devices
Full Time Employees

Key Executives

NameTitlePayExercisedYear Born
Mr. Gerard J. Michel MBA, MSCEO & Director671.6kN/A1963
Dr. Johnny John M.D.Senior Vice President Clinical Development & Medical Affairs472.16kN/A1964
Ms. Sandra PennellSenior VP of Finance and Principal Financial & Accounting OfficerN/AN/A1979
Dr. Martha S. Rook Ph.D.Chief Operating OfficerN/AN/A1972
Mr. David HoffmanGeneral Counsel, Corporate Secretary & Chief Compliance OfficerN/AN/AN/A
Dr. Vojislav Vukovic M.D., Ph.D.Chief Medical OfficerN/AN/A1967
Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. It also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.

Corporate Governance

Delcath Systems, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.